Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: HRMY stock price vs REGN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at REGN's multiple
Needs REGN P/E.
Implied fair value · at HRMY's multiple
Needs HRMY P/E.
Live quote
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: HRMY FY 2025 (ended Dec 31, 2025) · REGN FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
HARMONY BIOSCIENCES HOLDINGS, INC. · implied price per share
Bear
$42.25
Base
$49.71
Bull
$57.16
REGENERON PHARMACEUTICALS, INC. · implied price per share
Bear
$493.59
Base
$580.70
Bull
$667.80
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.19x
0.06x
Net debt / EBITDA
Leverage against operating earnings
-2.20x
-1.17x
Cash and equivalents
Liquid reserves on the balance sheet
$775.34M
$8.61B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Jazz Pharmaceuticals plc
HRMY vs JAZZ
SUPERNUS PHARMACEUTICALS, INC.
HRMY vs SUPN
Intra-Cellular Therapies, Inc.
HRMY vs ITCI
ACADIA PHARMACEUTICALS INC
HRMY vs ACAD
Vanda Pharmaceuticals Inc.
HRMY vs VNDA
LivaNova PLC
HRMY vs LIVN
AMGEN INC
HRMY vs AMGN
PFIZER INC
HRMY vs PFE
BRISTOL MYERS SQUIBB CO
HRMY vs BMY
BIOGEN INC.
HRMY vs BIIB
GILEAD SCIENCES, INC.
HRMY vs GILD
Seagate Technology Holdings plc
HRMY vs STX
$163.66M
$1.99B
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe HRMY can sustain its 21.5% revenue growth while maintaining current margin levels, then the stock looks worth owning because it trades below the P/E-based implied price and at lower EV and sales multiples than REGN.
HRMY trades at a discount on both earnings and sales multiples versus REGN, while the modeled P/E-based implied price suggests 16.1% upside from the current quote. The valuation case is supported by stronger growth and much lower absolute multiples, but the discount is not extreme given HRMY’s mixed quality profile.
Supporting Metrics
